PD
CLDX icon

Point72 (DIFC)’s Celldex Therapeutics CLDX Stock Holding History

Point72 (DIFC)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,446
Closed -$153K – 1627
2025
Q1 		$153K Buy
+8,446
New +$189K 0.01% 969
2024
Q4 		– Sell
-14,114
Closed -$480K – 1567
2024
Q3 		$480K Buy
14,114
+7,116
+102% +$271K 0.02% 664
2024
Q2 		$259K Sell
6,998
-4,232
-38% -$160K 0.01% 791
2024
Q1 		$471K Buy
+11,230
New +$461K 0.01% 764

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 (DIFC)'s CLDX Position: Q2 2025 in Review

Point72 (DIFC) sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 8,446 shares — an estimated $153K sold.

Point72 (DIFC) first reported a position in CLDX in Q1 2024 and held it in 4 quarters. The position peaked at $480K in Q3 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Point72 (DIFC) reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 8,446 Celldex Therapeutics shares in Q2 2025, an estimated $153K.
  • Point72 (DIFC) first reported a position in Celldex Therapeutics in Q1 2024 and held it in 4 quarters.
  • Point72 (DIFC)'s Celldex Therapeutics position peaked at $480K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.